Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk

Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots.

Online PR News – 16-April-2012 – Los Angeles, CA – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz. The new labels must make patients aware of the increased risk of blood clots associated with these and other birth control pills containing the synthetic hormone drospirenone.

The decision comes after an FDA advisory panel convened in December 2011 to discuss the future of Yaz after numerous research studies indicated that women who used the drug were at risk for developing serious complications, including deep vein thrombosis (DVT) and pulmonary embolism. While the panel ultimately voted 15-11 to allow the continued sale of Yaz, its members also recommended that Bayer update the drug’s warning labels.

Specifically, the FDA will require the new labels to inform consumers that research studies have indicated up to a threefold risk of developing blood clots in women who use contraceptives containing drospirenone versus those who use older types of birth control pills. FDA officials also advised women who to speak with their physician or other health care professional about the potential blood clot risk associated with any type of oral contraceptive before taking the drug.

Bayer is currently facing several thousand lawsuits filed in connection with blood clots and other complications caused by Yaz. Bellwether trials in the federal Yaz litigation were scheduled to begin in January but the presiding judge ordered both sides to mediation. Last month, the company announced that it settled approximately 70 of these claims and would consider additional settlements on a case-by-case basis. The bellwether trials are scheduled to resume at the end of April if mediation talks are unsuccessful.

Attorney Jeffrey Nadrich believes that more Yaz side effects lawsuits will continue to be filed if additional women are injured by the drug. Affected patients and their families may be eligible to file a claim for compensation. These individuals are encouraged to seek the aid of an experienced personal injury lawyer to discuss their legal rights.

Nadrich & Cohen LLP is offering confidential, no-cost consultations to women who experienced complications after using Yaz. Help is available by calling the firm’s injury hotline at 1-800-718-4658 or by completing an online contact form at www.yazbirthcontrolinjury.com.

Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California specializing in handling mass tort actions and representing individuals in cases involving pharmaceutical companies and medical device manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.

In addition to handling Yaz side effects claims, the firm is also actively investigating cases involving Actos, DePuy ASR hips, vaginal mesh, Zoloft, Fosamax, Paxil, Wright Conserve Hips, Stevens-Johnson Syndrome, Benzene, Reflex Sympathy Dystrophy, Fen Phen and Asbestos exposure. For more information, visit www.personalinjurylawcal.com.



Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025